NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Brokerages

NewAmsterdam Pharma (NASDAQ:NAMS) has earned a consensus rating of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $39.80.

Several brokerages have commented on NAMS. Scotiabank lifted their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $25.54, for a total value of $762,266.84. Following the completion of the transaction, the insider now owns 10,656,172 shares of the company’s stock, valued at $272,158,632.88. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 446,730 shares of company stock valued at $11,438,695 in the last quarter. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently made changes to their positions in the business. Quarry LP boosted its stake in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares in the last quarter. Barclays PLC boosted its stake in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at $128,000. HB Wealth Management LLC purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $224,000. Finally, XTX Topco Ltd purchased a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at $187,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Up 0.6 %

Shares of NAMS stock opened at $23.55 on Monday. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The firm has a 50-day moving average of $23.68 and a 200-day moving average of $19.81.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.